Compare FISI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FISI | IMMX |
|---|---|---|
| Founded | 1817 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.4M | 716.2M |
| IPO Year | 1999 | 2021 |
| Metric | FISI | IMMX |
|---|---|---|
| Price | $40.92 | $14.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.00 | $19.20 |
| AVG Volume (30 Days) | 130.3K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | ★ 231.27 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $19.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.61 | $1.94 |
| 52 Week High | $42.97 | $15.10 |
| Indicator | FISI | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 74.25 |
| Support Level | $41.00 | $7.96 |
| Resistance Level | $42.97 | N/A |
| Average True Range (ATR) | 0.66 | 0.90 |
| MACD | -0.21 | 0.35 |
| Stochastic Oscillator | 44.97 | 89.71 |
Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.